Compare Jumia Technologies AG - ADR (JMIA) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs 10X Genomics Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.36 (market cap $865.90M), while 10X Genomics Inc trades at $81.8 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 11.6× Jumia Technologies AG - ADR's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and 10X Genomics Inc for 92 Days on average.
| JMIA | TXG | |
|---|---|---|
Market Cap | $865.90M | $10.07B |
Volume | 1,695,227 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $97.74 |
52-Week Low | $5.69 | $11.48 |
Typical Hold Time | 28 Days | 92 Days |
Enterprise Value | $831.54M | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.74, down 0.88% with a bearish technical signal despite analyst optimism. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, though it remains unprofitable with negative margins. Recent $50M capital injection and operational improvements support the path toward EBITDA breakeven by year-end 2026.
Investment outlook balances analyst bullishness (71% buy ratings, $12 consensus target) against persistent profitability challenges. Key opportunities include African e-commerce growth and cost optimization, while risks center on execution timeline and competitive pressures. The stock offers speculative upside if turnaround milestones are met.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
